CoChat

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Cappetta, Donato, De Angelis, Antonella, Ciuffreda, Loreta Pia, Coppini, Raffaele, Cozzolino, Anna, Miccichè, Agostino, Dell'Aversana, Carmela, D’Amario, Domenico, Cianflone, Eleonora, Scavone, Cristina, Santini, Lorenzo, Palandri, Chiara, Naviglio, Silvio, Crea, Filippo, Rota, Marcello, Altucci, Lucia, Rossi, Francesco, Capuano, Annalisa, Urbanek, Konrad, Berrino, Liberato · 2020 · Pharmacological Research
Cited by 128

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The results of trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors raised the possibility that this class of drugs provides cardiovascular benefits independently from their anti-diabetic effects, although the mechanisms are unknown. Therefore, we tested the effects of SGLT2 inhibitor dapagliflozin on the progression of experimental heart disease in a non-diabetic model of heart failure with preserved ejection fraction. Dahl salt-sensitive rats were fed a high-salt diet to induce hypertension and diastolic dysfunction and were then treated with dapagliflozin for six weeks. Dapagliflozin ameliorated diastolic function as documented by echo-Doppler and heart catheterization, while blood pressure remained markedly elevated. Chronic in vivo treatment with dapagliflozin reduced diastolic Ca2+ and Na+ overload and increased Ca2+ transient amplitude in ventricular cardiomyocytes, although no direct action of dapagliflozin on isolated cardiomyocytes was observed. Dapagliflozin reversed endothelial activation and endothelial nitric oxide synthase deficit, with reduced cardiac inflammation and consequent attenuation of pro-fibrotic signaling. The potential involvement of coronary endothelium was supported by the endothelial upregulation of Na+/H+ exchanger 1in vivo and direct effects on dapagliflozin on the activity of this exchanger in endothelial cells in vitro. In conclusions, several mechanisms may cumulatively play a significant role in the dapagliflozin-associated cardioprotection. Dapagliflozin ameliorates diastolic function and exerts a positive effect on the myocardium, possibly targeting coronary endothelium. The lower degree of endothelial dysfunction, inflammation and fibrosis translate into improved myocardial performance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2020.104781

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 128

Metadata

Authors
Cappetta, D., De Angelis, A., Ciuffreda, L. P., Coppini, R., Cozzolino, A., Miccichè, A., Dell'Aversana, C., D’Amario, D., Cianflone, E., Scavone, C., Santini, L., Palandri, C., Naviglio, S., Crea, F., Rota, M., Altucci, L., Rossi, F., Capuano, A., Urbanek, K., & Berrino, L.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2020-07
Volume
157
Pages
104781
ISSN
1043-6618 (ISSN-L)
OpenAlex
W3022230909
Cited by
128
References
10
FWCI
10.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. https://app.cochat.ai/papers/10.1016/j.phrs.2020.104781
The paper
Cappetta, D., De Angelis, A., Ciuffreda, L. P., Coppini, R., Cozzolino, A., Miccichè, A., Dell'Aversana, C., D’Amario, D., Cianflone, E., Scavone, C., Santini, L., Palandri, C., Naviglio, S., Crea, F., Rota, M., Altucci, L., Rossi, F., Capuano, A., Urbanek, K., & Berrino, L. (2020). Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacological Research. https://doi.org/10.1016/j.phrs.2020.104781

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.